Pulmonary embolism treatment approach

To go back to the wikidoc page on VTE, click click here

Resident Survival Guide

Pulmonary Embolism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pulmonary Embolism from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
Assessment of Clinical Probability and Risk Scores
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Arterial Blood Gas Analysis
D-dimer
Biomarkers
Electrocardiogram
Chest X Ray
Ventilation/Perfusion Scan
Echocardiography
Compression Ultrasonography
CT
MRI
Treatment
Treatment approach
Medical Therapy
IVC Filter
Pulmonary Embolectomy
Pulmonary Thromboendarterectomy
Discharge Care and Long Term Treatment
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Follow-Up
Support group
Special Scenario
Pregnancy
Cancer
Trials
Landmark Trials
Case Studies
Case #1
Pulmonary embolism treatment approach On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary embolism treatment approach
CDC on Pulmonary embolism treatment approach
Pulmonary embolism treatment approach in the news
Blogs on Pulmonary embolism treatment approach
Directions to Hospitals Treating Pulmonary embolism treatment approach
Risk calculators and risk factors for Pulmonary embolism treatment approach

Editor(s)-In-Chief: C. Michael Gibson, M.S., M.D. [1], The APEX Trial Investigators; Associate Editor(s)-In-Chief: Joseph Nasr, M.D.[2]; Rim Halaby, M.D. [3]

This page provides algorithms about the treatment choices. For more details about the medical therapy, click here. For more details about embolectomy, click here.

Overview

Prompt recognition, diagnosis, and treatment of acute pulmonary embolism is critical. Management requires early risk stratification, timely anticoagulation unless absolutely contraindicated, and escalation to advanced therapy when there is cardiopulmonary compromise. The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline introduced five Acute PE Clinical Categories (A to E) to better guide care setting and therapy selection. Direct oral anticoagulants are preferred oral agents for most eligible patients. Low molecular weight heparin is preferred over unfractionated heparin for most patients requiring initial parenteral anticoagulation, whereas unfractionated heparin is generally favored when rapid reversal may be needed or advanced therapy is anticipated.

Step 1: Confirm PE

Shown below is an algorithm depicting the updated initial diagnostic approach to acute pulmonary embolism.

Diagnostic notes:

• PERC rule: Apply only when clinical gestalt suggests very low pretest probability.
• Age-adjusted D-dimer: In patients age 50 years or older, threshold = age × 10 μg/L FEU.
• YEARS algorithm: May be used in appropriate patients to reduce unnecessary CTPA.
• Pregnancy: Pregnancy-adapted YEARS may be used in selected pregnant patients.
• CTPA: Preferred imaging modality for most patients when not contraindicated.
• V/Q scan: Alternative when CTPA is contraindicated or undesirable.

Is the patient suspected to have acute PE hemodynamically unstable? (SBP <90 mmHg OR drop >40 mmHg lasting >15 min OR vasopressor dependent OR cardiac arrest)

Yes

No

Suspected high-risk PE

Suspected non-high-risk PE

Administer anticoagulation (if there is no absolute contraindication) and activate PERT

Assess clinical pretest probability of PE Use a validated tool: - Wells score for PE - Revised Geneva Score - Clinical gestalt

Is CTPA available immediately?

What is the clinical pretest probability?

No

Yes

Low clinical probability or very low risk by gestalt

Intermediate clinical probability

High clinical probability or PE most likely

Order echocardiography

Apply PERC rule

Order D-dimer (age adjusted threshold or YEARS algorithm)

Administer anticoagulation (if there is no absolute contraindication) during the diagnostic workup

Does the patient have RV overload?

Are all 8 PERC criteria met?

Is the D-dimer positive?

Order CTPA

Yes

No

No

Yes

PE excluded

Order CTPA

Positive

Negative

Positive

Negative

Is the patient unstable OR no other tests are available?

Is the patient stabilized AND CTPA is now available?

Order CTPA

PE is excluded

Order CTPA

Positive

Negative

Positive

Negative

PE is excluded

Consider advanced therapy or embolectomy pathway

Order CTPA

PE is confirmed

PE is excluded

PE is confirmed

PE is excluded

PE is confirmed

PE is excluded

Positive for PE

Negative for PE

PE is confirmed

PE is excluded

Risk Stratification

Risk stratification in acute pulmonary embolism guides level of monitoring, disposition, and consideration of advanced therapies. Contemporary management incorporates hemodynamic status, markers of right ventricular dysfunction, biomarkers, clinical severity scores, and evidence of end-organ hypoperfusion.

High-risk features include persistent hypotension, vasopressor requirement, or cardiac arrest.

Clinical severity tools that may support risk assessment include:

• PESI
• sPESI
• Hestia criteria
• Bova score

Markers of increased severity include:

• Right ventricular enlargement or dysfunction on echocardiography or CTPA
• Elevated troponin
• Elevated BNP or NT-proBNP
• Hypoxemia, tachypnea, or escalating oxygen requirement
• Lactate elevation or other evidence of end-organ hypoperfusion

Step 2: Acute PE Clinical Category and Initial Treatment

Shown below is an algorithm depicting the initial management of acute pulmonary embolism using the 2026 acute PE clinical categories.

Definitions used for risk stratification and category assignment:

• Low clinical severity score: PESI ≤85 (Class I to II) OR sPESI = 0 OR Hestia = 0 OR Bova ≤4
• Elevated clinical severity score: PESI >85 OR sPESI ≥1 OR Hestia ≥1 OR Bova >4
• RV dysfunction: RV/LV ratio >1.0 on CTPA or echocardiography, or RV hypokinesis on echo
• Abnormal biomarkers: Troponin above institutional upper limit of normal, or BNP / NT-proBNP elevation
• Respiratory modifier: RR >30/min, OR SpO₂ <90% on room air, OR substantial supplemental oxygen requirement, OR need for non-invasive ventilation
• Transient hypotension: SBP <90 mmHg OR drop >40 mmHg lasting <15 min OR responding to IV fluids
• Normotensive shock: End-organ hypoperfusion without persistent hypotension, such as elevated lactate, acute kidney injury, low urine output, mental status change, low cardiac index, or low MAP.

Assess the clinical severity category of acute PE

Category A or B Asymptomatic or symptomatic with low clinical severity

Category C Normotensive with elevated clinical severity and no end-organ hypoperfusion

Category D or E Incipient or overt cardiopulmonary failure

Begin anticoagulation Prefer outpatient management only if low risk, reliable follow up, and anticoagulation is accessible

Hospitalize Begin anticoagulation Monitor for RV dysfunction and deterioration

ICU or step-down care Activate PERT Begin parenteral anticoagulation Provide hemodynamic and respiratory support

Subsegmental PE?

Does the patient deteriorate?

Is there an absolute contraindication to systemic thrombolysis?

YES

NO

YES

NO

NO

YES

Individualize anticoagulation decision after assessing DVT, cancer, and recurrence risk

Continue standard management

Escalate to advanced therapy pathway

Continue current treatment and monitoring

Hold anticoagulation during thrombolytic infusion and give systemic thrombolysis

Catheter-directed therapy OR Surgical embolectomy

Does the patient fail to improve?

YES

NO

Catheter-directed therapy OR Surgical embolectomy OR Mechanical circulatory support in selected refractory cases

Continue with the same treatment

Initial Anticoagulation Therapy

Begin initial anticoagulation therapy in: ❑ Confirmed PE OR ❑ High or intermediate probability of PE while awaiting diagnostic tests

Is the patient high risk or non-high risk?

High risk or advanced therapy likely

Non-high risk

❑ Administer IV unfractionated heparin when rapid reversal may be needed, thrombolysis is planned, or procedures are anticipated.

Does the patient have: ❑ High risk of bleeding OR ❑ Severe renal failure?

Yes

No

❑ Administer unfractionated heparin: ❑ IV infusion preferred OR ❑ SC injection in selected patients

❑ Administer ONE of the following: ❑ SC low molecular weight heparin (preferred) ❑ SC fondaparinux ❑ IV unfractionated heparin ❑ SC unfractionated heparin

Transition to Oral Anticoagulation

Oral Anticoagulation Options for Acute PE

Agent	Parenteral lead-in required	Initial treatment dose	Maintenance dose	Notes
Apixaban	No	10 mg twice daily for 7 days	5 mg twice daily	Reduced dose 2.5 mg twice daily may be used later for extended therapy in selected patients.
Rivaroxaban	No	15 mg twice daily for 21 days	20 mg once daily with food	Reduced dose 10 mg daily may be used later for extended therapy in selected patients.
Edoxaban	Yes	After at least 5 days of parenteral anticoagulation	60 mg once daily	Dose reduction may be required in selected patients.
Dabigatran	Yes	After at least 5 days of parenteral anticoagulation	150 mg twice daily	Requires initial parenteral anticoagulation.
Warfarin	Yes	Start with parenteral overlap	Dose to target INR 2.0 to 3.0	Continue overlap for at least 5 days and until INR is at least 2.0 for at least 24 hours.

Step 3: Long Term Anticoagulation Therapy

The long term management of PE depends on recurrence risk, whether the event was associated with a major reversible risk factor, whether persistent risk factors are present, and the patient’s bleeding risk. For most non-cancer patients, a direct oral anticoagulant is preferred over vitamin K antagonist therapy when not contraindicated. In selected cancer patients, either a DOAC or low molecular weight heparin may be used, with LMWH favored when bleeding risk from certain GI or GU cancers or drug interactions is a concern. The risk versus benefit of extended anticoagulation therapy should be reassessed regularly, such as annually.

Has the patient completed the initial treatment phase?

Yes

No

What is the recurrence risk setting?

Continue initial phase therapy

Major reversible risk factor

Active cancer or persistent risk factor

No identifiable risk factor

Recurrent PE

Bleeding risk is high

Therapy for 3 to 6 months ❑ Apixaban OR ❑ Rivaroxaban OR ❑ Edoxaban OR ❑ Dabigatran OR ❑ Warfarin

Extended therapy while cancer is active or persistent risk remains ❑ DOAC OR ❑ LMWH

Extended therapy recommended ❑ Full dose DOAC initially THEN ❑ Reduced dose extended DOAC in selected patients OR ❑ Warfarin

Extended therapy recommended ❑ DOAC preferred OR ❑ Warfarin

Consider limiting therapy to 3 to 6 months ❑ Reassess bleeding modifiers ❑ Reevaluate periodically

Reassess the risk of bleeding and recurrence regularly

Low or moderate bleeding risk

High bleeding risk

Continue extended therapy

Consider stopping therapy after the initial treatment period

Step 4: Post PE Follow Up

Structured follow up after acute pulmonary embolism is important to assess symptoms, anticoagulation adherence, bleeding risk, recovery of functional status, and possible chronic thromboembolic pulmonary disease. Patients with persistent dyspnea or exercise limitation after PE should undergo further evaluation, commonly beginning with a V/Q scan when CTEPD or CTEPH is suspected.

• Confirm access to anticoagulation and follow up plan before discharge.
• Reassess dyspnea, exercise limitation, and functional impairment at follow up visits.
• Evaluate persistent symptoms after approximately 3 months for post-PE syndrome or chronic thromboembolic disease.
• Reassess bleeding risk and the ongoing need for anticoagulation periodically.

PESI / sPESI Risk Stratification Reference

PESI and sPESI may help identify patients at low risk for short term complications and may support outpatient treatment decisions when used together with clinical judgment and other discharge criteria.

• PESI
• sPESI

Key Practice Points and Common Pitfalls

• Direct oral anticoagulants are preferred oral agents for most eligible patients with acute PE.
• Low molecular weight heparin is preferred over unfractionated heparin for most non-high-risk patients requiring initial parenteral treatment.
• IV unfractionated heparin is preferred when thrombolysis, embolectomy, or another rapid change in therapy may be needed.
• Do not use outpatient treatment casually. It is appropriate only for carefully selected low-risk patients with reliable follow-up and immediate access to anticoagulation.
• Do not treat all intermediate-risk PE the same way. Presence of RV dysfunction, biomarkers, oxygen requirement, and clinical deterioration changes management intensity.
• Systemic thrombolysis is not routine therapy for stable patients. It is mainly reserved for patients with hemodynamic collapse or selected patients with significant deterioration and acceptable bleeding risk.
• Do not overuse IVC filters. They are generally reserved for acute VTE with an absolute contraindication to anticoagulation or selected failure cases.
• Do not forget follow up. Persistent dyspnea or functional limitation after PE should prompt evaluation for post-PE syndrome or chronic thromboembolic disease.
• Reassess anticoagulation duration deliberately. Extended therapy depends on recurrence risk, bleeding risk, and whether the event was associated with a major reversible risk factor.